# A Study of the Effectiveness of Cabozantinib in Combination With Nivolumab as First-line Treatment of Advanced Renal Cell Carcinoma (aRCC) in Adults

> **NCT05361434** · — · ACTIVE_NOT_RECRUITING · sponsor: **Ipsen** · enrollment: 311 (actual)

## Conditions studied

- Advanced Renal Cell Carcinoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05361434
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-09-26
- **Primary completion:** 2025-10-20
- **Final completion:** 2026-11-30
- **Target enrollment:** 311 (ACTUAL)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05361434

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05361434, "A Study of the Effectiveness of Cabozantinib in Combination With Nivolumab as First-line Treatment of Advanced Renal Cell Carcinoma (aRCC) in Adults". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT05361434. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*